Olorin: Combining Gene Flow with Exome Sequencing in Large Family Studies of Complex DiseaseMorris · Bioinformatics2012PDF285 KB
Sa1738 – Olorinab (Formerly Apd371), a Peripherally Restricted, Highly Selective, Full Agonist of the Cannabinoid Receptor 2 (CB2), Reduces Visceral Hypersensitivity in Animal ModelsCastro · Gastroenterology2019PDF257 KB
Olorinab (APD371), a Peripherally Acting, Highly Selective, Full Agonist of the Cannabinoid Receptor 2, Reduces Colitis-induced Acute and Chronic Visceral Hypersensitivity in RodentsCastro · Ovid Technologies (Wolters Kluwer Health)2021PDF2.4 MB
Su1930 – Safety and Efficacy of Olorinab, a Peripherally Restricted, Highly Selective, Cannabinoid Receptor 2 Agonist in a Phase 2A Study in Chronic Abdominal Pain Associated with Crohn’s DiseaseYacyshyn · Gastroenterology2019PDF628 KB
P418 Safety and Efficacy of Olorinab, a Peripherally Restricted, Highly-selective, Cannabinoid Receptor 2 Agonist in a Phase 2A Study in Chronic Abdominal Pain Associated with Crohn’s DiseaseHiggins · Journal of Crohn s and Colitis2019PDF84 KB
Sa1078 CANNABINOID RECEPTOR EXPRESSION AND THE EFFECT OF OLORINAB, A PERIPHERALLY ACTING, HIGHLY SELECTIVE, FULL AGONIST OF THE CANNABINOID RECEPTOR 2 (CB2), IN RODENTS WITH COLITIS AND CHRONIC VISCERAL HYPERSENSITIVITYCastro · Gastroenterology2020PDF738 KB
P139 OLORINAB, A PERIPHERALLY RESTRICTED, HIGHLY SELECTIVE AGONIST OF THE CANNABINOID RECEPTOR TYPE 2 FOR THE MANAGEMENT OF VISCERAL PAIN IN INFLAMMATORY BOWEL DISEASE (IBD) – PRECLINICAL AND EARLY CLINICAL DEVELOPMENTLindstrom · Gastroenterology2019PDF415 KB
Efficacy and safety of olorinab, a full agonist of the cannabinoid receptor 2, for the treatment of abdominal pain in patients with irritable bowel syndrome: Results from a phase 2b randomized placebo‐controlled trial ( CAPTIVATE )Chang · Neurogastroenterology & Motility2023PDF2.0 MB